Abstract
Paroxysmal nonkinesigenic dyskinesia (PNKD) is a rare movement disorder characterized by intermittent attacks of hyperkinetic involuntary movements without loss of consciousness. It may be classified into primary (genetic or sporadic) or secondary. The attacks usually occur at rest and may be precipitated by alcohol, coffee, cola, tobacco, fatigue, and emotion. Eighty percent of the patients are of autosomal dominant inheritance with a MR-1 gene mutation on chromosome 2q. Management is the avoidance of precipitating factors. Usually, medical treatment is less rewarding. Medications which have shown benefit in some include carbamazepine, benztropine, or clonazepam. Deep Brain Stimulation (ViM, or GPi target) might be considered in severe and medically refractory cases.
| Original language | English |
|---|---|
| Title of host publication | Current Clinical Neurology |
| Pages | 317-318 |
| Number of pages | 2 |
| DOIs | |
| State | Published - 2019 |
Publication series
| Name | Current Clinical Neurology |
|---|---|
| ISSN (Print) | 1559-0585 |
| ISSN (Electronic) | 2524-4043 |
Bibliographical note
Publisher Copyright:© 2019, Springer Nature Switzerland AG.
Keywords
- Dystonia
- Mitochondrial dysfunction
- Myofibrillogenesis regulator 1 gene
- Paroxysmal nonkinesigenic dyskinesia PNKD
- Sleep benefit
ASJC Scopus subject areas
- Clinical Neurology
Fingerprint
Dive into the research topics of 'Treatment of paroxysmal nonkinesigenic dyskinesia'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver